Meindert Danhof
#119,795
Most Influential Person Now
Meindert Danhof's AcademicInfluence.com Rankings
Meindert Danhofphilosophy Degrees
Philosophy
#5385
World Rank
#8163
Historical Rank
Logic
#2674
World Rank
#3697
Historical Rank
Download Badge
Chemistry Philosophy
Meindert Danhof's Degrees
- PhD Pharmaceutical Sciences University of Amsterdam
- Masters Pharmacy University of Groningen
Why Is Meindert Danhof Influential?
(Suggest an Edit or Addition)Meindert Danhof's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Drug transport across the blood-brain barrier (1992) (508)
- Therapeutic Drug Monitoring in Saliva (1978) (324)
- Buprenorphine induces ceiling in respiratory depression but not in analgesia. (2006) (289)
- Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. (2008) (274)
- Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. (2005) (259)
- Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. (2007) (258)
- Considerations in the Use of Cerebrospinal Fluid Pharmacokinetics to Predict Brain Target Concentrations in the Clinical Setting (2002) (228)
- Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on drug transport across the blood–brain barrier (1997) (221)
- Pharmacokinetic‐pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite α‐hydroxymidazolam in healthy volunteers (1992) (211)
- The role of population PK–PD modelling in paediatric clinical research (2010) (208)
- Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans (1987) (196)
- Extensions to the Visual Predictive Check to facilitate model performance evaluation (2008) (191)
- Mechanism-Based Pharmacokinetic–Pharmacodynamic Modeling—A New Classification of Biomarkers (2005) (179)
- Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in man. (1984) (177)
- Assay of antipyrine and its primary metabolites in plasma, saliva and urine by high-performance liquid chromatography and some preliminary results in man. (1979) (173)
- Clinical pharmacokinetics of pioglitazone (2000) (167)
- Characterization of an "in vitro" blood-brain barrier: effects of molecular size and lipophilicity on cerebrovascular endothelial transport rates of drugs. (1988) (150)
- Markers of disease severity in chronic obstructive pulmonary disease. (2006) (150)
- Morphine Glucuronidation in Preterm Neonates, Infants and Children Younger than 3 Years (2009) (149)
- A Mechanism-based Disease Progression Model for Comparison of Long-term Effects of Pioglitazone, Metformin and Gliclazide on Disease Processes Underlying Type 2 Diabetes Mellitus (2006) (141)
- What is the right dose for children? (2010) (140)
- Explaining Variability in Tacrolimus Pharmacokinetics to Optimize Early Exposure in Adult Kidney Transplant Recipients (2009) (136)
- Studies on the different metabolic pathways of antipyrine in rats: influence of phenobarbital and 3-methylcholanthrene treatment. (1979) (132)
- Electroencephalogram Effect Measures and Relationships Between Pharmacokinetics and Pharmacodynamics of Centrally Acting Drugs (1992) (128)
- Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo. (2005) (126)
- Relevance of the Application of Pharmacokinetic-Pharmacodynamic Modelling Concepts in Drug Development (1997) (125)
- Pharmacokinetic-pharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors. (2005) (124)
- Pharmacokinetic-pharmacodynamic modeling of the electroencephalographic effects of benzodiazepines. Correlation with receptor binding and anticonvulsant activity. (1991) (123)
- Naloxone Reversal of Buprenorphine-induced Respiratory Depression (1988) (116)
- Kinetics of drug action in disease states. I. Effect of infusion rate on phenobarbital concentrations in serum, brain and cerebrospinal fluid of normal rats at onset of loss of righting reflex. (1984) (116)
- Maturation of the Glomerular Filtration Rate in Neonates, as Reflected by Amikacin Clearance (2012) (113)
- NEGLIGIBLE SUBLINGUAL ABSORPTION OF NIFEDIPINE (1987) (112)
- Targeting liposomes with protein drugs to the blood-brain barrier in vitro. (2005) (111)
- Physiologically Based Pharmacokinetic Modeling to Investigate Regional Brain Distribution Kinetics in Rats (2012) (111)
- Critical factors of intracerebral microdialysis as a technique to determined the pharmacokinetics of drugs in rat brain (1994) (111)
- Body Weight-Dependent Pharmacokinetics of Busulfan in Paediatric Haematopoietic Stem Cell Transplantation Patients (2012) (109)
- Pharmacokinetic-Pharmacodynamic Modeling of the Antinociceptive Effect of Buprenorphine and Fentanyl in Rats: Role of Receptor Equilibration Kinetics (2005) (108)
- Nifedipine: Kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration (1986) (104)
- Systems pharmacology - Towards the modeling of network interactions. (2016) (104)
- Drug disposition in obesity: toward evidence-based dosing. (2015) (101)
- Validation of the Transferrin Receptor for Drug Targeting to Brain Capillary Endothelial Cells In Vitro (2004) (100)
- Pharmacokinetic‐pharmacodynamic modelling of the EEG effects of midazolam in individual rats: influence of rate and route of administration (1991) (95)
- Immune reconstitution kinetics as an early predictor for mortality using various hematopoietic stem cell sources in children. (2013) (95)
- Mechanism‐based PK/PD Modeling of the Respiratory Depressant Effect of Buprenorphine and Fentanyl in Healthy Volunteers (2007) (90)
- Disease System Analysis: Basic Disease Progression Models in Degenerative Disease (2005) (89)
- Differential effects of enzyme induction on antipyrine metabolite formation. (1982) (89)
- Pharmacokinetic-pharmacodynamic modeling of CNS drug effects: an overview. (1988) (88)
- Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling. (2009) (87)
- In vivo Target Residence Time and Kinetic Selectivity: The Association Rate Constant as Determinant. (2016) (86)
- Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling of the Electroencephalogram Effects of GABAA Receptor Modulators: In Vitro-in Vivo Correlations (2003) (86)
- Allometric Scaling of Clearance in Paediatric Patients: When Does the Magic of 0.75 Fade? (2016) (80)
- Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. (1998) (80)
- A Neonatal Amikacin Covariate Model Can Be Used to Predict Ontogeny of Other Drugs Eliminated Through Glomerular Filtration in Neonates (2013) (79)
- A Bodyweight-Dependent Allometric Exponent for Scaling Clearance Across the Human Life-Span (2012) (79)
- Simultaneous Pharmacokinetic Modeling of Gentamicin, Tobramycin and Vancomycin Clearance from Neonates to Adults: Towards a Semi-physiological Function for Maturation in Glomerular Filtration (2014) (78)
- Allometric relationships between the pharmacokinetics of propofol in rats, children and adults. (2005) (77)
- Mechanism-based pharmacokinetic-pharmacodynamic modeling of antilipolytic effects of adenosine A(1) receptor agonists in rats: prediction of tissue-dependent efficacy in vivo. (1999) (76)
- Mechanism-based Pharmacokinetic–Pharmacodynamic Modeling of the Antinociceptive Effect of Buprenorphine in Healthy Volunteers (2006) (75)
- Characterization and Modulation of the Transferrin Receptor on Brain Capillary Endothelial Cells (2004) (75)
- Studies on the different metabolic pathways of antipyrine in man. I. Oral administration of 250, 500 and 1000 mg to healthy volunteers. (1979) (75)
- Tailor-made drug treatment for children: creation of an infrastructure for data-sharing and population PK-PD modeling. (2009) (74)
- Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients. (2003) (74)
- Analysis of drug-receptor interactions in vivo: a new approach in pharmacokinetic-pharmacodynamic modelling. (1997) (73)
- Preclinical prediction of human brain target site concentrations: considerations in extrapolating to the clinical setting. (2011) (72)
- Mechanism-Based Pharmacokinetic-Pharmacodynamic Modelling of the Reversal of Buprenorphine-Induced Respiratory Depression by Naloxone (2007) (71)
- Prediction of Propofol Clearance in Children from an Allometric Model Developed in Rats, Children and Adults versus a 0.75 Fixed-Exponent Allometric Model (2010) (71)
- Developmental Changes in the Expression and Function of Cytochrome P450 3A Isoforms: Evidence from In Vitro and In Vivo Investigations (2013) (70)
- Pharmacokinetic considerations on Orgaran (Org 10172) therapy. (1992) (69)
- Pharmacokinetic-pharmacodynamic characterization of the cardiovascular, hypnotic, EEG and ventilatory responses to dexmedetomidine in the rat. (1997) (69)
- Systematic Evaluation of the Descriptive and Predictive Performance of Paediatric Morphine Population Models (2010) (67)
- Quantification of the EEG Effect of Midazolam by Aperiodic Analysis in Volunteers (1990) (67)
- Population Pharmacokinetics and Pharmacodynamics of Propofol in Morbidly Obese Patients (2011) (66)
- The exploration of rotenone as a toxin for inducing Parkinson's disease in rats, for application in BBB transport and PK-PD experiments. (2008) (66)
- Application of intracerebral microdialysis to study regional distribution kinetics of drugs in rat brain (1995) (66)
- The comparative pharmacodynamics of remifentanil and its metabolite, GR90291, in a rat electroencephalographic model. (1999) (65)
- Nifedipine: Influence of renal function on pharmacokinetic/hemodynamic relationship (1985) (64)
- Mechanism-based pharmacokinetic-pharmacodynamic modeling of the effects of N6-cyclopentyladenosine analogs on heart rate in rat: estimation of in vivo operational affinity and efficacy at adenosine A1 receptors. (1997) (63)
- Hemodynamic effects and histamine release elicited by the selective adenosine A3 receptor agonist 2-Cl-IB-MECA in conscious rats. (1996) (63)
- Influence of Different Fat Emulsion-Based Intravenous Formulations on the Pharmacokinetics and Pharmacodynamics of Propofol (1998) (62)
- Population pharmacokinetic modelling of non‐linear brain distribution of morphine: influence of active saturable influx and P‐glycoprotein mediated efflux (2007) (62)
- Population pharmacokinetic and pharmacodynamic modeling of propofol for long‐term sedation in critically ill patients: A comparison between propofol 6% and propofol 1% (2002) (62)
- Advances in paediatric pharmacokinetics (2011) (61)
- A pharmacodynamic Markov mixed‐effect model for the effect of temazepam on sleep (2000) (61)
- A Generic Multi-Compartmental CNS Distribution Model Structure for 9 Drugs Allows Prediction of Human Brain Target Site Concentrations (2016) (61)
- Individualized dosing regimens in children based on population PKPD modelling: are we ready for it? (2011) (60)
- Evidence-Based Morphine Dosing for Postoperative Neonates and Infants (2014) (60)
- Characterization of the pharmacodynamic interaction between parent drug and active metabolite in vivo: midazolam and alpha-OH-midazolam. (1999) (60)
- Disease Severity Is a Major Determinant for the Pharmacodynamics of Propofol in Critically Ill Patients (2008) (59)
- Ribose-modified adenosine analogues as potential partial agonists for the adenosine receptor. (1995) (58)
- Transdermal Iontophoresis of Rotigotine Across Human Stratum Corneum in Vitro: Influence of pH and NaCl Concentration (2004) (56)
- Mechanism-based pharmacokinetic-pharmacodynamic modeling of concentration-dependent hysteresis and biphasic electroencephalogram effects of alphaxalone in rats. (2002) (56)
- Pharmacokinetic‐pharmacodynamic modeling of midazolam effects on the human central nervous system (1988) (56)
- Pharmacokinetic-pharmacodynamic relationship of the cardiovascular effects of adenosine A1 receptor agonist N6-cyclopentyladenosine in the rat. (1994) (56)
- Determination of the threshold for convulsions by direct cortical stimulation (1989) (56)
- lontophoretic Delivery of Apomorphine I: In Vitro Optimization and Validation (1997) (56)
- Influence of single- and multiple-dose omeprazole treatment on nifedipine pharmacokinetics and effects in healthy subjects (2004) (55)
- Relationship between the metabolism of antipyrine, hexobarbitone and theophylline in man as assessed by a 'cocktail' approach. (1988) (54)
- Allometric Scaling of Pharmacodynamic Responses: Application to 5-Ht1A Receptor Mediated Responses from Rat to Man (2007) (54)
- Predicting Drug Concentration‐Time Profiles in Multiple CNS Compartments Using a Comprehensive Physiologically‐Based Pharmacokinetic Model (2017) (54)
- First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development (2012) (54)
- Prediction of human CNS pharmacokinetics using a physiologically‐based pharmacokinetic modeling approach (2018) (54)
- Pharmacokinetics and Pharmacodynamics of Midazolam and Metabolites in Nonventilated Infants after Craniofacial Surgery (2006) (54)
- Developmental Changes in Morphine Clearance Across the Entire Paediatric Age Range are Best Described by a Bodyweight-Dependent Exponent Model (2013) (54)
- Synergistic Combinations of Anticonvulsant Agents: What Is the Evidence from Animal Experiments? (2007) (53)
- A set-point model with oscillatory behavior predicts the time course of 8-OH-DPAT-induced hypothermia. (2001) (53)
- Propofol Pharmacokinetics and Pharmacodynamics for Depth of Sedation in Nonventilated Infants after Major Craniofacial Surgery (2006) (52)
- Critical Illness Is a Major Determinant of Midazolam Clearance in Children Aged 1 Month to 17 Years (2012) (52)
- In vivo characterization of the pharmacodynamic interaction of a benzodiazepine agonist and antagonist: midazolam and flumazenil. (1992) (51)
- Systemic and Direct Nose-to-Brain Transport Pharmacokinetic Model for Remoxipride after Intravenous and Intranasal Administration (2011) (51)
- Sensitivity of the individual items of the Hamilton depression rating scale to response and its consequences for the assessment of efficacy. (2008) (51)
- Predictive Performance of a Busulfan Pharmacokinetic Model in Children and Young Adults (2012) (51)
- A Model‐Based Approach to Dose Selection in Early Pediatric Development (2010) (51)
- Prediction of methotrexate CNS distribution in different species - influence of disease conditions. (2014) (51)
- The allometric exponent for scaling clearance varies with age: a study on seven propofol datasets ranging from preterm neonates to adults. (2014) (50)
- Pharmacokinetic–Pharmacodynamic Modeling of the Effectiveness and Safety of Buprenorphine and Fentanyl in Rats (2007) (49)
- Mechanism-based PK–PD model for the prolactin biological system response following an acute dopamine inhibition challenge: quantitative extrapolation to humans (2012) (49)
- Changes in GABAA receptor properties in amygdala kindled animals: In vivo studies using [11C]flumazenil and positron emission tomography (2009) (49)
- Transdermal iontophoresis of rotigotine: influence of concentration, temperature and current density in human skin in vitro. (2004) (49)
- Ontogeny of hepatic glucuronidation; methods and results. (2012) (46)
- Pharmacokinetics of Ceftazidime in Adult Cystic Fibrosis Patients During Continuous Infusion and Ambulatory Treatment at Home (1994) (46)
- Correlation between in vitro and in vivo concentration–effect relationships of naproxen in rats and healthy volunteers (2006) (46)
- From Pediatric Covariate Model to Semiphysiological Function for Maturation: Part I–Extrapolation of a Covariate Model From Morphine to Zidovudine (2012) (45)
- A Novel Maturation Function for Clearance of the Cytochrome P450 3A Substrate Midazolam from Preterm Neonates to Adults (2013) (45)
- The disposition of antipyrine and its metabolites in young and elderly healthy volunteers. (1987) (45)
- Transdermal iontophoresis of the dopamine agonist 5-OH-DPAT in human skin in vitro. (2005) (45)
- Markers of exacerbation severity in chronic obstructive pulmonary disease (2006) (44)
- Paediatric drug development: are population models predictive of pharmacokinetics across paediatric populations? (2011) (44)
- The impact of P-gp functionality on non-steady state relationships between CSF and brain extracellular fluid (2013) (44)
- Transport of vasopressin fragments across the blood-brain barrier: in vitro studies using monolayer cultures of bovine brain endothelial cells. (1989) (44)
- From Pediatric Covariate Model to Semiphysiological Function for Maturation: Part II—Sensitivity to Physiological and Physicochemical Properties (2012) (43)
- Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration. (2005) (43)
- Kinetics of drug action in disease states. II. Effect of experimental renal dysfunction on phenobarbital concentrations in rats at onset of loss of righting reflect. (1984) (43)
- Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling of the Respiratory-Depressant Effect of Buprenorphine and Fentanyl in Rats (2006) (43)
- Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling of 5-HT1A Receptor Agonists: Estimation of in Vivo Affinity and Intrinsic Efficacy on Body Temperature in Rats (2004) (42)
- Repeated microdialysis perfusions: periprobe tissue reactions and BBB permeability (1995) (42)
- Selectivity of action of 8‐alkylamino analogues of N6‐cyclopentyladenosine in vivo: haemodynamic versus anti‐lipolytic responses in rats (1998) (42)
- A study of the effects of long-term use on individual sensitivity to temazepam and lorazepam in a clinical population. (2003) (41)
- Animal-to-Human Extrapolation of the Pharmacokinetic and Pharmacodynamic Properties of Buprenorphine (2007) (41)
- Pharmacokinetic-Pharmacodynamic Modelling of the Interaction between Flumazenil and Midazolam in Volunteers by Aperiodic EEG Analysis (1991) (41)
- Markers of exacerbation severity in chronic obstructive pulmonary disease. (2006) (41)
- A competitive interaction model predicts the effect of WAY-100,635 on the time course of R-(+)-8-hydroxy-2-(di-n-propylamino)tetralin-induced hypothermia. (2002) (41)
- Pharmacokinetics and hemodynamic effects of nisoldipine and its interaction with cimetidine (1988) (41)
- Pharmacokinetics of Clindamycin in Pregnant Women in the Peripartum Period (2010) (41)
- Prospective Evaluation of a Model-Based Dosing Regimen for Amikacin in Preterm and Term Neonates in Clinical Practice (2015) (40)
- Explaining variability in ciclosporin exposure in adult kidney transplant recipients (2010) (40)
- Compartmental Modeling of Transdermal Iontophoretic Transport II: In Vivo Model Derivation and Application (2004) (40)
- Properties of the convulsive threshold determined by direct cortical stimulation in rats (1992) (39)
- Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020. (2012) (39)
- Commentary: "A systems view on the future of medicine: inspiration from Chinese medicine?". (2009) (39)
- Influence of the genetically controlled deficiency in debrisoquine hydroxylation on antipyrine metabolite formation. (1981) (39)
- Pharmacokinetic-Pharmacodynamic Modeling of Buspirone and Its Metabolite 1-(2-Pyrimidinyl)-piperazine in Rats (2002) (38)
- Pharmacokinetics, Enantiomer Interconversion, and Metabolism of R‐Apomorphine in Patients with Idiopathic Parkinson's Disease (1998) (38)
- Pharmacokinetic–Pharmacodynamic Model for the Reversal of Neuromuscular Blockade by Sugammadex (2009) (38)
- lontophoretic Delivery of Apomorphine II: An In Vivo Study in Patients with Parkinson's Disease (1997) (38)
- Influence of bile salts on hepatic transport of dibromosulphthalein. (1979) (38)
- Translation of drug effects from experimental models of neuropathic pain and analgesia to humans. (2012) (38)
- Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: A study of five different suppositories (1995) (38)
- Influence of feeding schedules on the chronobiology of renin activity, urinary electrolytes and blood pressure in dogs (2014) (38)
- Deoxyribose analogues of N6‐cyclopentyladenosine (CPA): partial agonists at the adenosine A1 receptor in vivo (1995) (37)
- Multivariate quantitative structure-pharmacokinetic relationships (QSPKR) analysis of adenosine A1 receptor agonists in rat. (1999) (37)
- Pharmacokinetic/pharmacodynamic relationship of benzodiazepines in the direct cortical stimulation model of anticonvulsant effect. (1996) (37)
- Coping with time scales in disease systems analysis: application to bone remodeling (2011) (36)
- High-performance liquid chromatography of nalbuphine, butorphanol and morphine in blood and brain microdialysate samples: application to pharmacokinetic/pharmacodynamic studies in rats. (2005) (36)
- In vitro iontophoresis of R-apomorphine across human stratum corneum. Structure-transport relationship of penetration enhancement. (2002) (36)
- Structural Models Describing Placebo Treatment Effects in Schizophrenia and Other Neuropsychiatric Disorders (2011) (36)
- Pharmacokinetics and effects of propofol 6% for short-term sedation in paediatric patients following cardiac surgery. (2002) (36)
- A comparison of the concentration-effect relationships of midazolam for EEG-derived parameters and saccadic peak velocity. (1993) (36)
- Pharmacokinetic-Pharmacodynamic Modeling of the Respiratory Depressant Effect of Norbuprenorphine in Rats (2007) (36)
- The Use of Intracerebral Microdialysis for the Determination of Pharmacokinetic Profiles of Anticancer Drugs in Tumor-Bearing Rat Brain (1995) (35)
- Characterization of endogenous viral loci in five lines of white Leghorn chickens. (1984) (35)
- Population pharmacokinetics of paracetamol across the human age‐range from (pre)term neonates, infants, children to adults (2014) (35)
- Stepwise Intravenous Infusion of Apomorphine to Determine the Therapeutic Window in Patients with Parkinson's Disease (1998) (34)
- Identifying the translational gap in the evaluation of drug-induced QTc interval prolongation. (2013) (34)
- Relevance of arteriovenous concentration differences in pharmacokinetic-pharmacodynamic modeling of midazolam. (1998) (34)
- Iontophoretic delivery of apomorphine. II: An in vivo study in patients with Parkinson's disease. (1997) (34)
- Microdialysis: the Key to Physiologically Based Model Prediction of Human CNS Target Site Concentrations (2017) (34)
- Pharmacokinetic-Pharmacodynamic Modeling of the D2 and 5-HT2A Receptor Occupancy of Risperidone and Paliperidone in Rats (2012) (34)
- Developmental pharmacokinetics of propylene glycol in preterm and term neonates. (2012) (33)
- Pharmacokinetic-pharmacodynamic modeling of the anticonvulsant and electroencephalogram effects of phenytoin in rats. (1998) (33)
- High-performance liquid chromatography of the neuroactive steroids alphaxalone and pregnanolone in plasma using dansyl hydrazine as fluorescent label: application to a pharmacokinetic-pharmacodynamic study in rats. (2000) (33)
- Long‐term sedation with propofol 60 mg ml−1 vs. propofol 10 mg ml−1 in critically ill, mechanically ventilated patients (2004) (33)
- 8-substituted adenosine and theophylline-7-riboside analogues as potential partial agonists for the adenosine A1 receptor. (1995) (33)
- Bone Physiology, Disease and Treatment (2010) (33)
- Application of a Combined “Effect Compartment/Indirect Response Model” to the Central Nervous System Effects of Tiagabine in the Rat (1999) (33)
- Pharmacokinetics, induction of anaesthesia and safety characteristics of propofol 6% SAZN vs propofol 1% SAZN and Diprivan-10 after bolus injection. (1999) (33)
- Characterization of the pharmacodynamics of several antiepileptic drugs in a direct cortical stimulation model of anticonvulsant effect in the rat. (1994) (32)
- Pilot study on the influence of liver blood flow and cardiac output on the clearance of propofol in critically ill patients (2008) (32)
- Functional role of adenosine receptor subtypes in the regulation of blood-brain barrier permeability: possible implications for the design of synthetic adenosine derivatives. (2003) (32)
- Body weight-dependent pharmacokinetics of busulfan in pediatric hematopoietic stem cell transplantation patients: towards individualized dosing (2013) (32)
- Stereoselective Transport of Baclofen Across the Blood–Brain Barrier in Rats as Determined by the Unit Impulse Response Methodology (1991) (31)
- Therapeutic efficacy of the adenosine A1 receptor agonist N6-cyclopentyladenosine (CPA) against organophosphate intoxication (2002) (31)
- Cutaneous side‐effects of transdermal iontophoresis with and without surfactant pretreatment: a single‐blinded, randomized controlled trial (2005) (31)
- Semiphysiologically based pharmacokinetic model for midazolam and CYP3A mediated metabolite 1‐OH‐midazolam in morbidly obese and weight loss surgery patients (2015) (31)
- Chronobiology of the renin-angiotensin-aldosterone system in dogs: relation to blood pressure and renal physiology (2013) (31)
- 3-Hydroxymethyl antipyrine excretion in urine after an oral dose of antipyrine. A reconsideration of previously published data and synthesis of a pure reference substance. (1982) (31)
- Assessing the Probability of Drug‐Induced QTc‐Interval Prolongation During Clinical Drug Development (2011) (31)
- Amoxicillin pharmacokinetics in pregnant women with preterm premature rupture of the membranes. (2008) (31)
- A system approach to pharmacodynamics. III: An algorithm and computer program, COLAPS, for pharmacodynamic modeling. (1991) (30)
- Predicting the “First dose in children” of CYP3A‐metabolized drugs: Evaluation of scaling approaches and insights into the CYP3A7‐CYP3A4 switch at young ages (2014) (30)
- Neuroactive Steroids Differ in Potency but Not in Intrinsic Efficacy at the GABAA Receptor in Vivo (2002) (29)
- The influence of labour on the pharmacokinetics of intravenously administered amoxicillin in pregnant women. (2008) (29)
- PKPD modelling of the interrelationship between mean arterial BP, cardiac output and total peripheral resistance in conscious rats (2013) (29)
- Dose-Dependent EEG Effects of Zolpidem Provide Evidence for GABAA Receptor Subtype Selectivity in Vivo (2003) (29)
- Population pharmacokinetic modelling of total and unbound cefazolin plasma concentrations as a guide for dosing in preterm and term neonates. (2014) (29)
- A new sublingual formulation of apomorphine in the treatment of patients with Parkinson's disease (1996) (28)
- Pharmacokinetic/Pharmacodynamic Modeling of Renin-Angiotensin Aldosterone Biomarkers Following Angiotensin-Converting Enzyme (ACE) Inhibition Therapy with Benazepril in Dogs (2015) (28)
- From Trial and Error to Trial Simulation. Part 2: An Appraisal of Current Beliefs in the Design and Analysis of Clinical Trials for Antidepressant Drugs (2009) (28)
- Evaluation of blood-brain barrier transport and CNS drug metabolism in diseased and control brain after intravenous L-DOPA in a unilateral rat model of Parkinson's disease (2012) (28)
- Population pharmacokinetics of ceftazidime in cystic fibrosis patients analyzed by using a nonparametric algorithm and optimal sampling strategy (1996) (28)
- Application of a mechanism-based disease systems model for osteoporosis to clinical data (2013) (28)
- Studies of the different metabolic pathways of antipyrine in man (1982) (28)
- Transdermal iontophoretic delivery of apomorphine in patients improved by surfactant formulation pretreatment. (2005) (28)
- Mechanistic models enable the rational use of in vitro drug-target binding kinetics for better drug effects in patients (2016) (28)
- Drug effects on the CVS in conscious rats: separating cardiac output into heart rate and stroke volume using PKPD modelling (2014) (28)
- Population pharmacodynamic modelling of lorazepam- and midazolam-induced sedation upon long-term continuous infusion in critically ill patients (2006) (28)
- Pharmacokinetics and hemodynamic effects of long-term nisoldipine treatment in hypertensive patients. (1989) (28)
- Non-invasive assessment of skin barrier integrity and skin irritation following iontophoretic current application in humans (1996) (27)
- Assay of R-apomorphine, S-apomorphine, apocodeine, isoapocodeine and their glucuronide and sulfate conjugates in plasma and urine of patients with Parkinson's disease. (1997) (27)
- Predictive Performance of a Recently Developed Population Pharmacokinetic Model for Morphine and its Metabolites in New Datasets of (Preterm) Neonates, Infants and Children. (2011) (27)
- Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: the role of complex biophase distribution kinetics. (2008) (27)
- The influence of infusion rate on the pharmacokinetics and haemodynamic effects of nisoldipine in man. (1988) (27)
- Challenges in translational drug research in neuropathic and inflammatory pain: the prerequisites for a new paradigm (2017) (27)
- Developmental changes rather than repeated administration drive paracetamol glucuronidation in neonates and infants (2015) (26)
- Validation and testing of a new iontophoretic continuous flow through transport cell. (1998) (26)
- Modelling and Simulation of the Positive and Negative Syndrome Scale (PANSS) Time Course and Dropout Hazard in Placebo Arms of Schizophrenia Clinical Trials (2012) (26)
- Influence of biophase distribution and P‐glycoprotein interaction on pharmacokinetic‐pharmacodynamic modelling of the effects of morphine on the EEG (2007) (26)
- Predictive Performance of a Recently Developed Population Pharmacokinetic Model for Morphine and its Metabolites in New Datasets of (Preterm) Neonates, Infants and Children (2011) (26)
- Pharmacokinetics and EEG Effects of Flumazenil in Volunteers (1991) (26)
- The in Vivo Study of Drug Action: Principles and Applications of Kinetic-Dynamic Modelling (1992) (26)
- Differences in the sensitivity of behavioural measures of pain to the selectivity of cyclo‐oxygenase inhibitors (2009) (26)
- Pharmacokinetic-pharmacodynamic modelling of the hypothermic and corticosterone effects of the 5-HT1A receptor agonist flesinoxan. (2002) (25)
- Pharmacokinetic interactions and dosing rationale for antiepileptic drugs in adults and children (2018) (25)
- Pharmacokinetic Modeling of Non-Linear Brain Distribution of Fluvoxamine in the Rat (2007) (25)
- A New Minimal-Stress Freely-Moving Rat Model for Preclinical Studies on Intranasal Administration of CNS Drugs (2009) (25)
- In vivo modeling of the pharmacodynamic interaction between benzodiazepines which differ in intrinsic efficacy. (1992) (25)
- Pooled population pharmacokinetic model of imipenem in plasma and the lung epithelial lining fluid. (2016) (25)
- From Trial and Error to Trial Simulation. Part 1: The Importance of Model‐Based Drug Development for Antidepressant Drugs (2009) (25)
- Adenosine A1 Receptor AgonistN 6-Cyclopentyladenosine Affects the Inactivation of Acetylcholinesterase in Blood and Brain by Sarin (2003) (25)
- Iontophoretic Delivery of Apomorphine In Vitro: Physicochemic Considerations (2001) (25)
- Pharmacodynamic Analysis of the Anticonvulsant Effects of Tiagabine and Lamotrigine in Combination in the Rat (2004) (25)
- Pharmacology-based toxicity assessment: towards quantitative risk prediction in humans. (2016) (25)
- Modeling of the effect site equilibration kinetics and pharmacodynamics of racemic baclofen and its enantiomers using quantitative EEG effect measures. (1992) (24)
- Population pharmacokinetic modelling of the enterohepatic recirculation of diclofenac and rofecoxib in rats (2008) (24)
- Pharmacokinetic-Pharmacodynamic Analysis of the EEG Effect of Alfentanil in Rats Followingβ-Funaltrexamine-Induced μOpioid Receptor “Knockdown”In Vivo (2000) (24)
- Pharmacokinetics of Penicillin G in Infants with a Gestational Age of Less than 32 Weeks (2007) (24)
- Pharmacokinetic–pharmacodynamic correlation of lamotrigine, flunarizine, loreclezole, CGP40116 and CGP39551 in the cortical stimulation model (2000) (24)
- The Impact of Arteriovenous Concentration Differences on Pharmacodynamic Parameter Estimates (1997) (24)
- Modelling of the pharmacodynamic interaction of an A1 adenosine receptor agonist and antagonist in vivo: N6‐cyclopentyladenosine and 8‐cyclopentyltheophylline (1995) (23)
- Pharmacokinetic modelling of the haemodynamic effects of the A2a adenosine receptor agonist CGS 21680C in conscious normotensive rats (1995) (23)
- Brain penetration of synthetic adenosine A1 receptor agonists in situ: role of the rENT1 nucleoside transporter and binding to blood constituents. (2005) (23)
- 8-Alkylamino-substituted analogs of N6-cyclopentyladenosine are partial agonists for the cardiovascular adenosine A1 receptors in vivo. (1997) (23)
- Assessment of Interspecies Differences in Drug-Induced QTc Interval Prolongation in Cynomolgus Monkeys, Dogs and Humans (2015) (23)
- Effect of Age-Related Factors on the Pharmacokinetics of Lamotrigine and Potential Implications for Maintenance Dose Optimisation in Future Clinical Trials (2018) (23)
- Pharmacokinetics and pharmacodynamics of propofol 6% SAZN versus propofol 1% SAZN and Diprivan-10 for short-term sedation following coronary artery bypass surgery (2000) (23)
- Kinetics of drug action in disease states. VII. Effect of experimental renal dysfunction on the pharmacodynamics of ethanol in rats. (1985) (23)
- Disposition of hexobarbital in the rat. Estimation of "first-pass" elimination and influence of ether anesthesia. (1983) (23)
- Generating Virtual Patients by Multivariate and Discrete Re-Sampling Techniques (2015) (23)
- Chronobiology and Pharmacologic Modulation of the Renin-Angiotensin-Aldosterone System in Dogs: What Have We Learned? (2015) (23)
- Mechanism-Based Pharmacokinetic–Pharmacodynamic Modeling of the Dopamine D2 Receptor Occupancy of Olanzapine in Rats (2011) (23)
- Pharmacokinetic‐pharmacodynamic modelling of S(−)‐atenolol in rats: reduction of isoprenaline‐induced tachycardia as a continuous pharmacodynamic endpoint (2007) (22)
- Coupling of Metal Containing Homing Devices to Liposomes via a Maleimide Linker: Use of TCEP to Stabilize Thiol-groups without Scavenging Metals (2004) (22)
- Pharmacokinetics and pharmacodynamics analysis of transdermal iontophoresis of 5-OH-DPAT in rats: in vitro-in vivo correlation. (2006) (22)
- Impact of efflux transporters and of seizures on the pharmacokinetics of oxcarbazepine metabolite in the rat brain (2008) (22)
- Pharmacometrics as a Discipline Is Entering the “Industrialization” Phase: Standards, Automation, Knowledge Sharing, and Training Are Critical for Future Success (2010) (22)
- Pharmacokinetic–pharmacodynamic modeling of antipsychotic drugs in patients with schizophrenia Part I: The use of PANSS total score and clinical utility (2013) (22)
- Kinetics of drug action in disease states. V. Acute effect of urea infusion on phenobarbital concentrations in rats at onset of loss of righting reflex. (1985) (22)
- On the reliability of affinity and efficacy estimates obtained by direct operational model fitting of agonist concentration-effect curves following irreversible receptor inactivation. (1997) (21)
- Drugs Being Eliminated via the Same Pathway Will Not Always Require Similar Pediatric Dose Adjustments (2018) (21)
- Pharmacokinetic‐pharmacodynamic modelling of the EEG effect of alfentanil in rats: assessment of rapid functional adaptation (1998) (21)
- Pharmacokinetic–Pharmacodynamic Analysis of the Static Allodynia Response to Pregabalin and Sildenafil in a Rat Model of Neuropathic Pain (2010) (21)
- Seizure patterns in kindling and cortical stimulation models of experimental epilepsy (1997) (21)
- Capturing the dynamics of systemic Renin-Angiotensin-Aldosterone System (RAAS) peptides heightens the understanding of the effect of benazepril in dogs. (2013) (21)
- High-performance liquid chromatography of the adenosine A1 agonist N6-cyclopentyladenosine and the A1 antagonist 8-cyclopentyltheophylline and its application in a pharmacokinetic study in rats. (1993) (21)
- Physiological Indirect Effect Modeling of the Antilipolytic Effects of Adenosine A1-Receptor Agonists (1997) (20)
- ASSESSMENT AND PREDICTION OF IN VIVO OXIDATIVE DRUG METABOLIZING ACTIVITY (1984) (20)
- The unit impulse response procedure for the pharmacokinetic evaluation of drug entry into the central nervous system (1989) (20)
- Prediction of Headache Response in Migraine Treatment (2006) (20)
- Modelling of the pharmacodynamics and pharmacodynamic interactions of CNS active drugs. (1992) (20)
- Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats. (1997) (20)
- The Use of Intracerebral Microdialysis to Determine Changes in Blood-Brain Barrier Transport Characteristics (2004) (20)
- Correlation between midazolam and lignocaine pharmacokinetics and MEGX formation in healthy volunteers. (2002) (19)
- Not-in-trial simulation I: Bridging cardiovascular risk from clinical trials to real-life conditions. (2013) (19)
- Pharmacokinetics of Amoxicillin in Maternal, Umbilical Cord, and Neonatal Sera (2009) (19)
- Rate of change of blood concentrations is a major determinant of the pharmacodynamics of midazolam in rats (1999) (19)
- Mechanism-Based Pharmacodynamic Modeling of the Interaction of Midazolam, Bretazenil, and Zolpidem with Ethanol (2002) (19)
- Pharmacokinetic modeling of the anticonvulsant response of oxazepam in rats using the pentylenetetrazol threshold concentration as pharmacodynamic measure (1988) (19)
- Stability and pharmacokinetics of flumazenil in the rat (2005) (19)
- Population pharmacokinetics of deferiprone in healthy subjects. (2014) (19)
- Antipyrine metabolite formation in children in the acute phase of malnutrition and after recovery. (1980) (19)
- Population Pharmacokinetic Analysis for Simultaneous Determination of Bmax and KDIn Vivo by Positron Emission Tomography (2005) (19)
- Scaling of pharmacokinetics across paediatric populations: the lack of interpolative power of allometric models. (2012) (19)
- Compartmental Modeling of Transdermal Iontophoretic Transport: I. In Vitro Model Derivation and Application (2004) (19)
- Adaptive trials in paediatric development: dealing with heterogeneity and uncertainty in pharmacokinetic differences in children. (2012) (19)
- Individualized Dosing Algorithms and Therapeutic Monitoring for Antiepileptic Drugs (2018) (19)
- Pharmacokinetic‐pharmacodynamic modelling of the anti‐lipolytic and anti‐ketotic effects of the adenosine A1‐receptor agonist N6‐(p‐sulphophenyl)adenosine in rats (1997) (19)
- Propofol 6% as sedative in children under 2 years of age following major craniofacial surgery. (2005) (19)
- Kinetics of drug action in disease states: towards physiology-based pharmacodynamic (PBPD) models (2015) (19)
- Sensitivity of the Montgomery Asberg Depression Rating Scale to response and its consequences for the assessment of efficacy. (2009) (19)
- Pharmacodynamics of temazepam in primary insomnia: Assessment of the value of quantitative electroencephalography and saccadic eye movements in predicting improvement of sleep (1997) (18)
- The future of drug development: the paradigm shift towards systems therapeutics. (2018) (18)
- Influence of plasma protein binding on pharmacodynamics: Estimation of in vivo receptor affinities of beta blockers using a new mechanism-based PK-PD modelling approach. (2009) (18)
- Covariate effects and population pharmacokinetics of lamivudine in HIV-infected children. (2014) (18)
- Modeling and simulation for medical product development and evaluation: highlights from the FDA-C-Path-ISOP 2013 workshop (2014) (18)
- Prediction of Morphine Clearance in the Paediatric Population (2012) (17)
- Estimation of amobarbital plasma-effect site equilibration kinetics. Relevance of polyexponential conductance functions (1991) (17)
- Online solid phase extraction with liquid chromatography-tandem mass spectrometry to analyze remoxipride in small plasma-, brain homogenate-, and brain microdialysate samples. (2010) (17)
- Blood-brain barrier transport of synthetic adenosine A1 receptor agonists in vitro: structure transport relationships. (2003) (17)
- Pharmacokinetic modeling of the anticonvulsant action of phenobarbital in rats. (1989) (17)
- Partial agonism of theophylline-7-riboside on adenosine receptors (1994) (17)
- A population analysis of the pharmacokinetics and pharmacodynamics of midazolam in the rat (1991) (17)
- Sacubitril/valsartan (LCZ696) Significantly Reduces Aldosterone and Increases cGMP Circulating Levels in a Canine Model of RAAS Activation (2018) (16)
- A Semiphysiological Population Model for Prediction of the Pharmacokinetics of Drugs under Liver and Renal Disease Conditions (2011) (16)
- Phannacokinetic‐pharmacodynamic modelling of the anticonvulsant effect of oxazepam in individual rats (1990) (16)
- Translational Modeling in Schizophrenia: Predicting Human Dopamine D2 Receptor Occupancy (2016) (16)
- Analysis of the Relationship Between Age and Treatment Response in Migraine (2009) (16)
- Population Pharmacokinetic-Pharmacodynamic Modeling of Haloperidol in Patients With Schizophrenia Using Positive and Negative Syndrome Rating Scale (2013) (16)
- Levofloxacin‐Induced QTc Prolongation Depends on the Time of Drug Administration (2016) (16)
- Analysis of responses in migraine modelling using hidden Markov models (2007) (16)
- Modeling and Simulation at the Interface of Nonclinical and Early Clinical Drug Development (2013) (16)
- The implications of target saturation for the use of drug–target residence time (2018) (16)
- Adaptive changes in the pharmacodynamics of midazolam in different experimental models of epilepsy: kindling, cortical stimulation and genetic absence epilepsy (1998) (15)
- Pharmacodynamic characterization of the electroencephalographic effects of thiopental in rats (1991) (15)
- Mechanism-Based Modeling of Functional Adaptation Upon Chronic Treatment with Midazolam (2000) (15)
- Assay of 3-carboxy-antipyrine in urine by capillary gas chromatography with nitrogen selective detection. Some preliminary results in man. (1979) (15)
- Drug transport across the blood-brain barrier (1993) (15)
- Pretreatment with a Water-Based Surfactant Formulation Affects Transdermal Iontophoretic Delivery of R-Apomorphine in Vitro (2003) (15)
- Physiological red blood cell kinetic model to explain the apparent discrepancy between adenosine breakdown inhibition and nucleoside transporter occupancy of draflazine. (1998) (15)
- Effect of Elastic Liquid-State Vesicle on Apomorphine Iontophoresis Transport Through Human Skin In Vitro (2001) (14)
- Low but Inducible Contribution of Renal Elimination to Clearance of Propylene Glycol in Preterm and Term Neonates (2014) (14)
- Iontophoretic R-apomorphine delivery in combination with surfactant pretreatment: in vitro validation studies. (2003) (14)
- Pharmacotherapy in pediatric epilepsy: from trial and error to rational drug and dose selection – a long way to go (2016) (14)
- The influence of dosage time of midazolam on its pharmacokinetics and effects in humans (1991) (14)
- Pharmacokinetic–pharmacodynamic modelling of behavioural responses (1998) (14)
- Progesterone in saliva: pitfalls and consequent implications for accuracy of the determination. (1986) (14)
- Strategy to Assess the Role of (Inter)active Metabolites in Pharmacodynamic Studies In‐vivo: a Model Study with Heptabarbital (1988) (14)
- The Population Approach: Measuring and Managing Variability in Response, Concentration and Dose, Commission of the European Community, Luxembourg (1997) (14)
- The missing link between clinical endpoints and drug targets in depression. (2010) (14)
- Radioimmunoassay of desglycinamide-arginine vasopressin and its application in a pharmacokinetic study in the rat (1988) (14)
- Pharmacodynamic interaction between midazolam and a low dose of ethanol in vivo. (1995) (14)
- Population pharmacokinetics of abacavir in infants, toddlers and children. (2013) (14)
- The influence of dosage time of midazolam on its pharmacokinetics and effects in humans. (1992) (14)
- The in vitro and in vivo evaluation of new synthesized prodrugs of 5-OH-DPAT for iontophoretic delivery. (2010) (13)
- Metabolic and cardiovascular effects of the adenosine A1 receptor agonist N6-(p-sulfophenyl)adenosine in diabetic Zucker rats: influence of the disease on the selectivity of action. (1998) (13)
- Current issues relating to drug safety especially with regard to the use of biomarkers: a meeting report and progress update. (2007) (13)
- Population Pharmacokinetic Model of the Pregabalin-Sildenafil Interaction in Rats: Application of Simulation to Preclinical PK-PD Study Design (2009) (13)
- Understanding the Behavior of Systems Pharmacology Models Using Mathematical Analysis of Differential Equations: Prolactin Modeling as a Case Study (2016) (13)
- 5.38 – Mechanism-Based Pharmacokinetic–Pharmacodynamic Modeling for the Prediction of In Vivo Drug Concentration–Effect Relationships – Application in Drug Candidate Selection and Lead Optimization (2007) (13)
- Mechanism-Based Modeling of the Pharmacodynamic Interaction of Alphaxalone and Midazolam in Rats (2003) (13)
- Pharmacodynamic Analysis of the Interaction between Tiagabine and Midazolam with an Allosteric Model That Incorporates Signal Transduction (2003) (12)
- The contribution of nisoldipine-induced changes in liver blood flow to its pharmacokinetics after oral administration. (1989) (12)
- Pharmacokinetic–pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia: Part II: The use of subscales of the PANSS score (2013) (12)
- Evaluation of the Impact of UGT Polymorphism on the Pharmacokinetics and Pharmacodynamics of the Novel PPAR Agonist Sipoglitazar (2013) (12)
- Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of heptabarbital using aperiodic EEG analysis (1990) (12)
- Pharmacokinetic‐pharmacodynamic modelling in the early development phase of anti‐psychotics: a comparison of the effects of clozapine, S 16924 and S 18327 in the EEG model in rats (2001) (12)
- Dopamine D2 Receptor Occupancy as a Predictor of Catalepsy in Rats: A Pharmacokinetic-Pharmacodynamic Modeling Approach (2014) (12)
- Population pharmacokinetic model of fluvoxamine in rats: utility for application in animal behavioral studies. (2007) (12)
- Target and Tissue Selectivity Prediction by Integrated Mechanistic Pharmacokinetic-Target Binding and Quantitative Structure Activity Modeling (2017) (12)
- Inter‐study variability of preclinical in vivo safety studies and translational exposure–QTc relationships – a PKPD meta‐analysis (2015) (12)
- Translational Pharmacokinetic Modeling of Fingolimod (FTY720) as a Paradigm Compound Subject to Sphingosine Kinase-Mediated Phosphorylation (2014) (12)
- Pharmacokinetic/pharmacodynamic modelling of the anti-hyperalgesic and anti-nociceptive effect of adenosine A1 receptor partial agonists in neuropathic pain. (2005) (12)
- Integration of PKPD relationships into benefit–risk analysis (2015) (12)
- Kinetics of drug action in disease states XII: Effect of experimental liver diseases on the pharmacodynamics of phenobarbital and ethanol in rats. (1985) (12)
- Effect of amygdala kindling on the central nervous system effects of tiagabine: EEG effects versus brain GABA levels (2000) (12)
- Mechanistic model for the acute effect of fluvoxamine on 5-HT and 5-HIAA concentrations in rat frontal cortex. (2008) (12)
- Disease Progression Analysis: Towards Mechanism-Based Models (2011) (12)
- Pharmacodynamic interaction between phenytoin and sodium valproate changes seizure thresholds and pattern (1998) (11)
- Pharmacokinetic–pharmacodynamic modelling of fluvoxamine 5‐HT transporter occupancy in rat frontal cortex (2008) (11)
- Influence of covariate distribution on the predictive performance of pharmacokinetic models in paediatric research. (2014) (11)
- Pharmacodynamics of the anticonvulsant effect of oxazepam in aging BN/BiRij rats (1992) (11)
- The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine. (1996) (11)
- Population pharmacokinetic-pharmacodynamic modelling of S 15535, a 5-HT(1A) receptor agonist, using a behavioural model in rats. (2001) (11)
- Model-based evaluation of drug-induced QTc prolongation for compounds in early development. (2015) (11)
- In vitro and in silico analysis of the effects of D 2 receptor antagonist target binding kinetics on the cellular response to fluctuating dopamine concentrations (2018) (11)
- Prediction of Disease Progression, Treatment Response and Dropout in Chronic Obstructive Pulmonary Disease (COPD) (2014) (11)
- Increased sensitivity to the anesthetic effect of phenobarbital in aging BN/BiRij rats. (1992) (10)
- Exploring genetic and non-genetic risk factors for delayed graft function, acute and subclinical rejection in renal transplant recipients. (2016) (10)
- Anticonvulsant drugs differentially suppress individual ictal signs: a pharmacokinetic/pharmacodynamic analysis in the cortical stimulation model in the rat. (2003) (10)
- Sensitivity of pharmacokinetic-pharmacodynamic analysis for detecting small magnitudes of QTc prolongation in preclinical safety testing. (2015) (10)
- Pharmacodynamics of tolerance development to the anesthetic and anticonvulsant effects of phenobarbital in rats. (1990) (10)
- Model-based analysis of thromboxane B₂ and prostaglandin E₂ as biomarkers in the safety evaluation of naproxen. (2014) (10)
- A Combined Specific Target Site Binding and Pharmacokinetic Model to Explore the Non-linear Disposition of Draflazine (1999) (10)
- Effect of altered AGP plasma binding on heart rate changes by S(-)-propranolol in rats using mechanism-based estimations of in vivo receptor affinity (K(B,vivo)). (2010) (10)
- Application of ED-optimality to screening experiments for analgesic compounds in an experimental model of neuropathic pain (2012) (10)
- Structure-Based Prediction of Anti-infective Drug Concentrations in the Human Lung Epithelial Lining Fluid (2016) (10)
- Prediction of antiepileptic drug efficacy: the use of intracerebral microdialysis to monitor biophase concentrations (2009) (10)
- Mechanistic studies of the transdermal iontophoretic delivery of 5-OH-DPAT in vitro. (2010) (10)
- Stereoselective central nervous system effects of the R‐ and S‐isomers of the GABA uptake blocker N‐(4,4‐di‐(3‐methylthien‐2‐yl)but‐3‐enyl) nipecotic acid in the rat (1999) (10)
- Future delivery systems for apomorphine in patients with Parkinson's disease. (1999) (10)
- Model‐based prediction of the acute and long‐term safety profile of naproxen in rats (2015) (10)
- Interaction Study between Org 10172, a Low Molecular Weight Heparinoid, and Acetylsalicylic Acid in Healthy Male Volunteers (1991) (10)
- Applications of pharmacokinetic/pharmacodynamic research in rational drug development. (1996) (10)
- Quantification of the in vivo potency of the adenosine A2 receptor antagonist 8-(3-chlorostyryl)caffeine. (1995) (9)
- Evaluation of the long-term durability and glycemic control of fasting plasma glucose and glycosylated hemoglobin for pioglitazone in Japanese patients with type 2 diabetes. (2015) (9)
- Systems Pharmacology Analysis of the Amyloid Cascade after β-Secretase Inhibition Enables the Identification of an Aβ42 Oligomer Pool (2016) (9)
- Time course of action of three adenosine A1 receptor agonists with differing lipophilicity in rats: comparison of pharmacokinetic, haemodynamic and EEG effects (1997) (9)
- Enantioselective high-performance liquid chromatographic analysis of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin. Application to a pharmacokinetic-pharmacodynamic study in rats. (2000) (9)
- Pharmacokinetic‐haemodynamic relationships of 2‐chloroadenosine at adenosine A1 and A2a receptors in vivo (1996) (9)
- Diclofenac plasma protein binding: PK-PD modelling in cardiac patients submitted to cardiopulmonary bypass. (1997) (9)
- Variability in the Pharmacokinetics of Nisoldipine as Caused by Differences in Liver Blood Flow Response (1989) (9)
- A model-based approach to treatment comparison in acute migraine. (2006) (9)
- A controlled-release matrix tablet of furosemide: design, in vitro evaluation, pharmacological and pharmacodynamic evaluation (1988) (9)
- Disease Systems Analysis of Bone Mineral Density and Bone Turnover Markers in Response to Alendronate, Placebo, and Washout in Postmenopausal Women (2016) (9)
- Evaluation of treatment response in depression studies using a Bayesian parametric cure rate model. (2008) (9)
- Relevance of Absorption Rate and Lag Time to the Onset of Action in Migraine (2008) (9)
- hiGhly Active AntiretrovirAl therApy in children (2013) (9)
- The design of a dry-coated controlled-release tablet for oxprenolol with microporous polypropylene powder (1989) (9)
- Pharmacokinetic‐EEG effect relationship of midazolam in aging BN/BiRij rats (1992) (9)
- Decreased Efficacy of GABAA‐receptor Modulation by Midazolam in the Kainate Model of Temporal Lobe Epilepsy (2007) (8)
- A comparison of two semi-mechanistic models for prolactin release and prediction of receptor occupancy following administration of dopamine D2 receptor antagonists in rats. (2016) (8)
- Altered pharmacokinetic-pharmacodynamic relationship of heptabarbital in experimental renal failure in rats. (1988) (8)
- Liquid chromatography-thermospray tandem mass spectrometry for identification of a heptabarbital metabolite and sample work-up artefacts. (1991) (8)
- Pharmacokinetic-pharmacodynamic modelling of the cardiovascular effects of R- and S-N6-phenylisopropyladenosine in conscious normotensive rats. (1995) (8)
- Partial agonism of the nonselective adenosine receptor agonist 8-butylaminoadenosine at the A1 receptor in vivo. (1996) (8)
- Sampling Optimization in Pharmacokinetic Bridging Studies: Example of the Use of Deferiprone in Children With β‐Thalassemia (2016) (8)
- Mechanism-Based Pharmacodynamic Modeling of S(–)-Atenolol: Estimation of in Vivo Affinity for the β1-Adrenoceptor with an Agonist-Antagonist Interaction Model (2008) (8)
- Application of a systems pharmacology model for translational prediction of hERG‐mediated QTc prolongation (2016) (8)
- Biophase equilibration times. (1991) (7)
- A model‐based approach to analyze the influence of UGT2B15 polymorphism driven pharmacokinetic differences on the pharmacodynamic response of the PPAR agonist sipoglitazar (2014) (7)
- Application of a Systems Pharmacology-Based Placebo Population Model to Analyze Long-Term Data of Postmenopausal Osteoporosis (2015) (7)
- Semi-mechanistic Modelling of the Analgesic Effect of Gabapentin in the Formalin-Induced Rat Model of Experimental Pain (2014) (7)
- Translating QT interval prolongation from conscious dogs to humans (2017) (7)
- Pharmacokinetic–pharmacodynamic modelling of drug‐induced QTc interval prolongation in man: prediction from in vitro human ether‐à‐go‐go‐related gene binding and functional inhibition assays and conscious dog studies (2016) (7)
- Population analysis of the non linear red blood cell partitioning and the concentration-effect relationship of draflazine following various infusion rates. (1997) (7)
- Effects of repeated seizure induction on seizure activity, post-ictal and interictal behavior (1998) (7)
- Establishing in vitro to clinical correlations in the evaluation of cardiovascular safety pharmacology. (2013) (7)
- Pharmacokinetic-pharmacodynamic modelling of the analgesic effect of alfentanil in the rat using tooth pulp evoked potentials. (1998) (7)
- Population Pharmacokinetic Modeling of Blood-Brain Barrier Transport of Synthetic Adenosine A1 Receptor Agonists (2004) (7)
- Mechanism-Based Modeling of Adaptive Changes in the Pharmacodynamics of Midazolam in the Kindling Model of Epilepsy (1999) (7)
- Dosing Rationale for Fixed‐Dose Combinations in Children: Shooting From the Hip? (2012) (7)
- Effects of the adenosine A1 receptor allosteric modulators PD 81,723 and LUF 5484 on the striatal acetylcholine release. (2002) (7)
- Reproducible and time-dependent modification of serum protein binding in Wistar Kyoto rats. (2007) (7)
- Population pharmacokinetic modelling of the enterohepatic recirculation of diclofenac and rofecoxib in rats (2008) (7)
- A model-based approach for the evaluation of once daily dosing of lamivudine in HIV-infected children. (2014) (7)
- A Pediatric Covariate Function for CYP3A-Mediated Midazolam Clearance Can Scale Clearance of Selected CYP3A Substrates in Children (2019) (6)
- Characterization of the pharmacokinetics, brain distribution, and therapeutic efficacy of the adenosine A1 receptor partial agonist 2'-deoxy-N6-cyclopentyladenosine in sarin-poisoned rats. (2003) (6)
- From Trial and Error to Trial Simulation III: A Framework for Interim Analysis in Efficacy Trials With Antidepressant Drugs (2011) (6)
- Application of serial sampling of cerebrospinal fluid in pharmacodynamic studies with a drug active in the CNS: Heptabarbital concentrations at onset and offset of loss of righting reflex in rats (1988) (6)
- Pharmaco-electroencephalography and pharmacokinetic-pharmacodynamic modeling in drug development: focus on preclinical steps. (2002) (6)
- Drug transport across the blood — brain barrier (1992) (6)
- Determination of dexmedetomidine in rat plasma by a sensitive [3H]clonidine radioreceptor assay. (1997) (6)
- SC9 “animal welfare” in the cortical stimulation model for epilepsy research in the rat (1994) (6)
- Characterization and Prediction of Cardiovascular Effects of Fingolimod and Siponimod Using a Systems Pharmacology Modeling Approach (2017) (6)
- Extending a Systems Model of the APP Pathway: Separation of β- and γ-Secretase Sequential Cleavage Steps of APP (2018) (6)
- Modelling the delay between pharmacokinetics and EEG effects of morphine in rats: binding kinetic versus effect compartment models (2018) (6)
- Pharmacokinetic-pharmacodynamic modelling of tiagabine CNS effects upon chronic treatment in rats: lack of change in concentration-EEG effect relationship. (2000) (6)
- The influence of Org 10172, a low molecular weight heparinoid, on antipyrine metabolism and the effect of enzyme induction on the response to Org 10172. (1991) (6)
- Kinetics of drug action in disease states. IV. Effect of pregnancy on phenobarbital concentrations at onset of loss of righting reflex in rats. (1985) (5)
- Transdermal iontophoretic delivery of a novel series of dopamine agonists in vitro: physicochemical considerations (2010) (5)
- Urinary metabolite profile of antipyrine as a tool in the assessment of oxidative drug metabolizing capacity of man (1980) (5)
- A simple HPLC-fluorescence method for the measurement of R,S-sotalol in the plasma of patients with life-threatening cardiac arrhythmias. (2000) (5)
- Influence of Chlorthalidone on the Pharmacokinetics and Pharmacodynamics of Org 10172 (Lomoparan®), A Low Molecular Weight Heparinoid, in Healthy Volunteers (1991) (5)
- Prediction of Attack Frequency in Migraine Treatment (2008) (5)
- II. Experimental techniques to study drug transport (1992) (5)
- FIRST-IN-CLASS ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITOR LCZ696 MODULATES THE DYNAMICS OF THE RENIN CASCADE AND NATRIURETIC PEPTIDES SYSTEM WITH SIGNIFICANT REDUCTION OF ALDOSTERONE EXPOSURE (2014) (5)
- The variability in beta‐cell function in placebo‐treated subjects with type 2 diabetes: application of the weight‐HbA1c‐insulin‐glucose (WHIG) model (2017) (5)
- Peptide transport across the blood-brain barrier☆ (1990) (5)
- Low efficacy adenosine A1 agonists inhibit striatal acetylcholine release in rats improving central selectivity of action (2003) (5)
- Comparative analysis of the sensitivity of the individual items of the Montgomery Asberg depression rating scale to response and its consequences for the assessment of efficacy (2008) (5)
- Impact of chronic inflammation on the pharmacokinetic–pharmacodynamic relationship of naproxen (2010) (5)
- Model-Based Optimisation of Deferoxamine Chelation Therapy (2015) (5)
- Sensitivity of individual items of the Positive and Negative Syndrome Scale (PANSS) and items subgroups to differentiate between placebo and drug treatment in schizophrenia (2013) (5)
- Studies on the different metabolic pathways of antipyrine as a tool in the assessment of the activity of different drug metabolizing enzyme systems in man [proceedings]. (1980) (5)
- Population pharmacokinetic-pharmacodynamic modelling of the anti-hyperalgesic effect of 5'deoxy-N6-cylopentyladenosine in the mononeuropathic rat. (2004) (5)
- The pharmacokinetics and pharmacological effect of (S)-5-OH-DPAT following controlled delivery with transdermal iontophoresis. (2011) (5)
- The impact of composite AUC estimates on the prediction of systemic exposure in toxicology experiments (2015) (5)
- Pharmacokinetic-pharmacodynamic modelling in pre-clinical investigations: principles and perspectives (2011) (4)
- Pharmacokinetic-pharmacodynamic modelling of the anti-lipolytic effects of the adenosine A1-receptor agonist N6-(P-sulfophenyl)adenosine (SPA) in rats (1995) (4)
- Impact of disease, drug and patient adherence on the effectiveness of antiviral therapy in pediatric HIV (2017) (4)
- The Role of the Blood-Brain Barrier (2009) (4)
- Kinetics of drug action in disease states. VI. Effect of experimental diabetes on phenobarbital concentrations in rats at onset of loss of righting reflex. (1985) (4)
- Electroencephalography parameters as biomarkers: extrapolation from laboratory animals to humans. (2002) (4)
- Translational PKPD modeling in schizophrenia: linking receptor occupancy of antipsychotics to efficacy and safety (2012) (4)
- The use of intracerebral microdialysis to study blood-brain barrier transport in health, after modification and in disease. (1993) (4)
- Drug transport to the brain: in vitro versus in vivo approaches (1994) (4)
- Pharmacokinetic-pharmacodynamic modeling of the effect of fluvoxamine on p-chloroamphetamine-induced behavior. (2007) (4)
- Modelling of the pharmacodynamic interaction between phenytoin and sodium valproate (1998) (4)
- Population pharmacokinetic-pharmacodynamic model of propofol in adolescents undergoing scoliosis surgery with intraoperative wake-up test: a study using Bispectral index and composite auditory evoked potentials as pharmacodynamic endpoints (2019) (4)
- Application of the Convection–Dispersion Equation to Modelling Oral Drug Absorption (2006) (4)
- Scaling clearance of propofol from preterm neonates to adults using an allometric model with a bodyweight dependent maturational exponent (2010) (3)
- Pharmacokinetic-pharmacodynamic modelling of the anticonvulsant effect (1990) (3)
- Studies of interaction of a low-molecular-weight heparinoid (Org 10172) with cloxacillin and ticarcillin in healthy male volunteers (1991) (3)
- Maturation of GFR in Preterm and Term Neonates Reflected by Clearance of Different Antibiotics (2011) (3)
- Correction to: Modelling the delay between pharmacokinetics and EEG effects of morphine in rats: binding kinetic versus effect compartment models (2018) (3)
- Abstracts of papers (2005) (3)
- FC20 ribose modified adenosine analogues as potential partial agonists for the adenosine receptor (1994) (3)
- PK/PD modelling of reversal of neuromuscular blockade by a chemically optimised cyclodextrin (2004) (3)
- Oral controlled drug delivery systems based on microporous polymers (1989) (3)
- Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats (1996) (3)
- Cyclopentyladenosine and some of its low-efficacy derivatives inhibit striatal synaptosomal release of acetylcholine to a similar degree. (2003) (3)
- Biomarker exposure–response relationships as the basis for rational dose selection: Lessons from a simulation exercise using a selective COX‐2 inhibitor (2016) (3)
- Bridging Strategies for Drug Combinations in Pediatric Indications (2012) (2)
- Pilot study in humans on the pharmacokinetics and safety of propofol 6% SAZN (1999) (2)
- Changes in GABA A receptor properties in amygdala kindled animals: in vivo studies using [ 11 C]flumazenil and positron emission tomography (2008) (2)
- Optimizing the Busulfan Dosing Regimen to Get a More Predictable Exposure: A Data Driven Analysis (2011) (2)
- Heterogeneity in patient response in depression: The relevance of functional data analysis (2008) (2)
- PKPD modelling of drug-induced QTc interval prolongation in man : prediction from in vitro hERG binding and functional inhibition assays and conscious dog studies (2016) (2)
- A Generic Multi-Compartmental CNS Distribution Model Structure for 9 Drugs Allows Prediction of Human Brain Target Site Concentrations (2016) (2)
- Modeling of prolactin response following dopamine D2 receptor antagonists in rats: can it be translated to clinical dosing? (2017) (2)
- Differences in the in vitro and in vivo concentration-effect relationship of selective and non-selective COX inhibitors : role of translational pharmacology in pain research (2008) (2)
- Exposure-response relationship of typical and atypical antipsychotics assessed by the positive and negative syndrome scale (PANSS) and its subscales (2011) (2)
- Erratum: A model-based approach to dose selection in early pediatric development (Clinical Pharmacology and Therapeutics (2010) 87 294-302 doi:10.1038/clpt.2009.234) (2010) (2)
- Drug–Disease Model-Based Development of Therapeutic Agents for Treatment of Diabetes (2014) (2)
- Population analysis of the non-linear red blood cell partitioning of draflazine following various infusion durations (1997) (2)
- Pharmacokinetic/pharmacodynamic modelling: Extrapolation from animals to humans (1996) (2)
- Interaction of ORG 10172, a low molecular weight heparinoid, and digoxin in healthy volunteers (2004) (2)
- HEPATIC TRANSPORT MECHANISMS - INFLUENCE OF CHOLERESIS ON BILIARY-EXCRETION OF ORGANIC-COMPOUNDS (1976) (2)
- Interaction of the combined medication with the new low-molecular-weight heparinoid Lomoparan (Org 10172) and acenocoumarol. (1990) (2)
- ORGARAN Extending the Frontiers of Venous Thrombosis Prophylaxis (1992) (2)
- Summary data of potency and parameter information from semi-mechanistic PKPD modeling of prolactin release following administration of the dopamine D2 receptor antagonists risperidone, paliperidone and remoxipride in rats (2016) (2)
- Optimised protocol design for the screening of analgesic compounds in neuropathic pain (2012) (2)
- [Individualized dosing guidelines for children]. (2013) (2)
- Correction to: Effect of Age-Related Factors on the Pharmacokinetics of Lamotrigine and Potential Implications for Maintenance Dose Optimisation in Future Clinical Trials (2018) (1)
- Chapter 7 Pharmacokinetics of amoxicillin in maternal , umbilical cord and neonatal serum (2009) (1)
- Preclinical Pharmacodynamics of Central Nervous System Active Agents (1993) (1)
- THE EEG EFFECT OF FLUMAZENIL VS PLACEBO IN VOLUNTEERS (1989) (1)
- Erratum to: Microdialysis: the Key to Physiologically Based Model Prediction of Human CNS Target Site Concentrations (2017) (1)
- Quantitative EEG analysis: a biomarker for epileptogenesis (2008) (1)
- A Appendix : Analysis of responses in migraine modelling using hidden Markov models (2007) (1)
- Evaluation of blood-brain barrier transport and CNS drug metabolism in diseased and control brain after intravenous L-DOPA in a unilateral rat model of Parkinson's disease (2012) (1)
- Does size matter? Bridging and dose selection in paediatric trials (2008) (1)
- Paracetamol pharmacokinetics in term and preterm neonates (2010) (1)
- Top-Down Modeling Meets Bottom-Up Modeling: The Physiological and Physiochemical Basis for the Ontogeny of UGT2B7-Mediated Drug Glucuronidation (2012) (1)
- POPULATION PHARMACOKINETIC MODELLING OF BLOOD-BRAIN BARRIER TRANSPORT OF SYNTHETIC ADENOSINE A 1 RECEPTOR AGONISTS (2004) (1)
- Markers of pharmacological and toxicological action (2001) (1)
- Erratum to: Translational Modeling in Schizophrenia: Predicting Human Dopamine D2 Receptor Occupancy (2016) (1)
- Determination of Benzodiazepines: The Present-Day Scene (1986) (1)
- Pharmacokinetic-pharmacodynamic modelling of the hemodynamic and anti-lipolytic effects of 8-alkyl-amino-N6-cyclopentyladenosine (1996) (1)
- Assessment of the enantiomeric purity of R- and S-N6-phenylisopropyladenosine (PIA): Implications for adenosine receptor subclassification (1994) (1)
- Systemic- and direct nose-to-brain transport in the rat; a pharmacokinetic model for remoxipride after intravenous and intranasal administration (2011) (1)
- Prospective evaluation of cardiovascular safety in early clinical development: a case study with methadone. (2017) (1)
- Relationship between receptor occupancy at 37 degrees C and the anticonvulsant effect of flunitrazepam in rats. (1989) (1)
- Decreased efficacy of GABA A receptor modulation by midazolam in the kainate model of temporal lobe epilepsy (2008) (1)
- Evaluation of a mechanism-based pharmacokinetic-pharmacodynamic model for D2 receptorb occupancy of olanzapine in rats (2010) (1)
- Mechanism-based modelling of CNS drug effect: from receptor pharmacology to clinical trial (2001) (1)
- P.6.017 Pharmacokinetic-pharmacodynamic modelling of the interaction between phenytoin and sodium valproate (1996) (1)
- Increased Sensitivity to the Anticonvulsant Effect of Valproate in Aging BN/BiRij Rats (1993) (1)
- MODELLING OF THE ELECTROENCEPHALOGRAM EFFECTS OF MORPHINE: INFLUENCE OF BIOPHASE DISTRIBUTION AND P-GLYCOPROTEIN INTERACTION (2007) (1)
- Simultaneous Pharmacokinetic Modeling of Gentamicin, Tobramycin and Vancomycin Clearance from Neonates to Adults: Towards a Semi-physiological Function for Maturation in Glomerular Filtration (2014) (1)
- Knowledge in Ferment (2007) (1)
- Liquid chromatographic determination of the adenosine receptor agonist CGS 21680 in blood using on-line solid-phase extraction on a phenylboronic acid support and fluorescence detection. (1994) (1)
- Translation of drug-induced QTc prolongation in early drug development (2011) (1)
- Title: Uncertainty and decision making in clinical development: the impact of an interim analysis based on the posterior predictive power on depression trials (2008) (1)
- Prediction of headache response after migraine treatment using a Markov model (2007) (1)
- Generating Virtual Patients by Multivariate and Discrete Re-Sampling Techniques (2015) (0)
- Mechanism-based PK/PD modelling and biomarkers (2005) (0)
- PK/PD modelling of the anticonvulsant and EEG effects of phenytoin (1995) (0)
- Chapter 5 The Intracerebral Rotenone Model of Parkinson ' s Disease in Rats : Altered Conversion of L-DOPA into DOPAC and HVA without Changes in BBB Transport (2009) (0)
- PROSPECTIVE VALIDATION OF A MODEL-BASED DOSING REGIMEN FOR AMIKACIN IN NEONATES: FEASIBLE AND RELEVANT (2015) (0)
- Issue Information (2015) (0)
- Therapeutic efficacy in organophosphate poisoning by inhibiting central release of acetylcholine (2004) (0)
- PHARMACOKINETIC-PHARMACODYNAMIC MODELING OF THE EEG EFFECTS OF MIDAZOLAM IN VOLUNTEERS (1989) (0)
- Propylene glycol pharmacokinetics in preterm and term infants (2012) (0)
- INNOVATIVE PAEDIATRIC PHARMACOLOGY; VALIDATION OF AN EVIDENCE-BASED DOSING ALGORITHM FOR MORPHINE IN NEONATES AND INFANTS (2013) (0)
- Evaluation of the Long-term Durability and Glycemic Control of FPG and HbA1c for Pioglitazone in Japanese Patients with Type 2 Diabetes (2015) (0)
- Abstracts of papers clinical pharmacological meeting (2005) (0)
- Extrapolation of the developmental glomerular filtration rate model derived form amikacin clearance to netilmicin and vancomycin in preterm and term neonates (2012) (0)
- Challenges in translational drug research in neuropathic and inflammatory pain: the prerequisites for a new paradigm (2017) (0)
- Towards a mechanistic disease progression model for type 2 diabetes mellitusthe long-term efficacy of pioglitazone vs metformin and sulphonylurea (2004) (0)
- Abstracts of papers clinical pharmacological meeting (2005) (0)
- Chapter 6 Clavulanic acid does not influence amoxicillin pharmacokinetics in pregnant women during labor (2009) (0)
- 0070Translational prediction of sensitivity to hERG-mediated QTc-prolongation using a systems pharmacology model (2016) (0)
- Contents, Vol. 22, 1981 (1981) (0)
- Abstracts of papers (2005) (0)
- Transdermal iontophoresis of dopaminergic (pro) drugs : from formulation to in vivo application (2005) (0)
- Disposition of Heptabarbitone in the Rat: Identification of a New Metabolite by Tandem Mass Spectrometry (1992) (0)
- Predicting Glomerular Filtration Rate Using the Clearance of Amikacin in Neonates–Model Evaluation (2010) (0)
- Pharmacokinetic-Pharmacodynamic Modeling of the D2 and 5-HT2A Receptor Occupancy of Risperidone and Paliperidone in Rats (2012) (0)
- Development of dopaminergic (pro)drugs for programmed iontophoretic delivery into patients with Parkinson's disease (2005) (0)
- THE MISSING LINK BETWEEN CLINICAL ENDPOINT AND PHARMACOLOGICAL RECEPTOR SYSTEMS IN DEPRESSION (2009) (0)
- Modelling the delay between PK and EEG effects of morphine in rats ; binding kinetic versus effect compartment models (2018) (0)
- Relationship Between Receptor Occupancy at 37°C and the Anticonvulsant Effect of Flunitrazepam in Rats (1989) (0)
- Mechanism-Based Pharmacodynamic Modeling for Prediction of Exposure Response (2004) (0)
- Optimisation of liposomes targeted to the transferrin receptor on the in vitro blood-brain barrier (2003) (0)
- Microdialysis: the Key to Physiologically Based Model Prediction of Human CNS Target Site Concentrations (2017) (0)
- Maturation of Glomerular Filtration Rate in Preterm and Term Neonates as Reflected by Clearance of Amikacin, Netilmicin, and Vancomycin (2012) (0)
- Pharmacokinetic-pharmacodynamic modeling of the relationship between D2 receptor occupancy and catalepsy in rats: Predicting extrapyramidal side effects in humans (2012) (0)
- 1 Benefit-Risk Analysis : the current situation (2015) (0)
- KD in vivo by positron emission tomography (2008) (0)
- Predicting dopamine D2 receptor occupancy in humans using a physiology-based approach (2011) (0)
- Studies onthedifferent metabolic pathways of antipyrine asatool intheassessment ofthe activity ofdifferent drugmetabolizing enzyme systems inman (1979) (0)
- Pharmacokinetic-pharmacodynamic modelling of the flumazenil-midazolam interaction in rats (1990) (0)
- Age-related changes in oxidative drug metabolism versus pathological and nutritional condition and drug consumption (1991) (0)
- Assessment of Interspecies Differences in Drug-Induced QTc Interval Prolongation in Cynomolgus Monkeys, Dogs and Humans (2015) (0)
- Sampling optimisation in pharmacokinetic bridging studies: use of deferiprone in children with β-thalassaemia (2015) (0)
- A Pediatric Covariate Function for CYP3A-Mediated Midazolam Clearance Can Scale Clearance of Selected CYP3A Substrates in Children (2019) (0)
- Issue Information (2017) (0)
- From trial and error to trial simulation: An appraisal of current beliefs in clinical research practice in depression (2008) (0)
- Modelling ofthepharmacodynamic interaction ofan Al adenosine receptor agonist andantagonist invivo: N6-cyclopentyladenosine and8-cyclopentylthe ophylline (1995) (0)
- Authors’ Reply to Standing et al.: “Effect of Age-Related Factors on the Pharmacokinetics of Lamotrigine and Potential Implications for Maintenance Dose Optimisation in Future Clinical Trials” (2018) (0)
- Chapter 7.new.qxd (2008) (0)
- The impact of P-gp functionality on non-steady state relationships between CSF and brain extracellular fluid (2013) (0)
- A disease model for iron overload in patients affected by transfusion-dependent diseases (2015) (0)
- Oral paper abstracts (2022) (0)
- Erratum to: Microdialysis: the Key to Physiologically Based Model Prediction of Human CNS Target Site Concentrations (2017) (0)
- Pharmacokinetics and cardiovascular pharmaco-dynamics in rats of three adenosine A1-receptor agonists with differing lipophilicity (1995) (0)
- Developmental changes rather than repeated administration drive paracetamol glucuronidation in neonates and infants (2015) (0)
- Optimised protocol design for the screening of analgesic compounds in neuropathic pain (2012) (0)
- Structure-Based Prediction of Anti-infective Drug Concentrations in the Human Lung Epithelial Lining Fluid (2015) (0)
- Semi-mechanistic Modelling of the Analgesic Effect of Gabapentin in the Formalin-Induced Rat Model of Experimental Pain (2013) (0)
- Glomerular filtration rate in preterm and term neonates reflected by clearance of different antibiotics (2011) (0)
- A Neonatal Amikacin Covariate Model Can Be Used to Predict Ontogeny of Other Drugs Eliminated Through Glomerular Filtration in Neonates (2013) (0)
- RESILIENCE MECHANISM OF THE AMYLOID PRECURSOR PROTEIN (APP) PATHWAY REVEALED BY SYSTEMS PHARMACOLOGY MODELING FOLLOWING β- AND GAMMA-SECRETASE INHIBITION (2017) (0)
- Model-Based Optimisation of Deferoxamine Chelation Therapy (2015) (0)
- Non-renal and renal elimination of propylene glycol in neonates (2012) (0)
- time course of 8-OH-DPAT-induced hypothermia A set-point model with oscillatory behavior predicts the (2016) (0)
- Chapter 5 Comparative evaluation of sedation guidelines and clinical practice in long-term sedated critically ill patients (2007) (0)
- Application of ED-optimality to screening experiments for analgesic compounds in an experimental model of neuropathic pain (2012) (0)
- General introduction: what is the right dose for children? (2011) (0)
- Erratum to: Translational Modeling in Schizophrenia: Predicting Human Dopamine D2 Receptor Occupancy (2016) (0)
- Absorption mechanisms and design of delivery systems (2001) (0)
- Bespiegelingen over Farmacologie = Reflections on Pharmacology (2017) (0)
- Interaction of liposomes with lipopolysaccharide: influence of time, serum and liposome composition (2005) (0)
- IDENTIFICATION OF THE OPERATIONAL MODEL OF AGONISM FOR THE EEG EFFECTS OF OPIOIDS: ESTIMATION OF THE IN VIVO AFFINITY AND INTRINSIC EFFICACY AT THE -OPIOID RECEPTOR (2007) (0)
- Predictive value of allometric scaling for estimation of propofol clearance in neonates, infants and adolescents (2008) (0)
- Kinetics of drug action in disease states: towards physiology-based pharmacodynamic (PBPD) models (2015) (0)
- Correction to: Modelling the delay between pharmacokinetics and EEG effects of morphine in rats: binding kinetic versus effect compartment models (2018) (0)
- Molecular mechanisms and drug design (2001) (0)
- University of Groningen Modeling of prolactin response following dopamine Dreceptor antagonists in rats (2018) (0)
- Age and the Pharmacokinetic-Pharmacodynamic Relationship of Phenobarbital in Rats: “Pseudo”-Longitudinal vs Cross-Sectional Study Design (1992) (0)
- Drug monitoring and dose individualisation of anti-epileptic drugs : a role for pharmacometrics (2018) (0)
- Towards predictive cardiovascular safety : a systems pharmacology approach (2014) (0)
- Prediction of attack frequency in migraine : a Markov approach (2007) (0)
- A1213 EEG EFFECTS DURING 'STEADY STATE' INFUSION OF MIDAZOLAMDEVELOPMENT OF ACUTE TOLERANCE? (1990) (0)
- Thecontribution ofnisoldipine-indu ced changes inliver blood flowtoits pharmacokinetics after oral administration (1989) (0)
- Transdermal iontophoretic delivery of a novel series of dopamine agonists in vitro (2010) (0)
- Analysis of the Amyloid Cascade after b-Secretase Inhibition Enables the Identification of an A b 42 Oligomer Pool s (2016) (0)
- Developmental Changes in Glomerular Filtration Rate from Neonates until Adults (2014) (0)
- Ictal activity and interictal behaviour in the cortical stimulation model for epilepsy research (1995) (0)
- Abstracts of papers and posters Pharmacological Meeting (1994) (0)
- Target and Tissue Selectivity Prediction by Integrated Mechanistic Pharmacokinetic-Target Binding and Quantitative Structure Activity Modeling (2017) (0)
- SYSTEMS PHARMACOLOGY ANALYSIS OF THE Aβ OLIGOMER RESPONSE FOLLOWING BACE1 INHIBITION: EVIDENCE FOR SECOND-ORDER Aβ42 OLIGOMERIZATION (2017) (0)
- MIDAZOLAM CONCENTRATION‐EFFECT RELATIONSHIPS USING GUIDED INFUSIONS. (1992) (0)
- influence of covAriAte distribution on model predictive performAnce (2013) (0)
- P1371 The infiuence of uterine contractions during labour on the pharmacokinetics of intravenously administered amoxicillin (2007) (0)
- forGiveness of non-Adherence for different clAsses of AntiretrovirAl druGs in children (2013) (0)
- Modelling the delay between pharmacokinetics and EEG effects of morphine in rats: binding kinetic versus effect compartment models (2018) (0)
- Pharmacokinetic-pharmacodynamic modeling of dopamine D2 receptor occupancy in humans using Bayesian modeling tools (2011) (0)
- Population pharmacokinetic analysis to guide cefazolin dosing in preterm and term neonates (2014) (0)
- The impact of composite AUC estimates on the prediction of systemic exposure in toxicology experiments (2015) (0)
- the allometric exponent for maturation in propofol clearance varies with age (2011) (0)
- Identifying risk factors for delayed graft function, acute rejection and subclinical acute rejection in renal transplant recipients on controlled cyclosporine exposure (2014) (0)
- Aberrant amoxicillin pharmacokinetics in a pregnant patient with severe vomiting: a case-report. (2009) (0)
- The implications of target saturation for the use of drug–target residence time (2018) (0)
- Application of a mechanism-based disease systems model for osteoporosis to clinical data (2013) (0)
- Dosing recommendation rationale for fixed-dose combinations in children: a shoot from the hip? (2011) (0)
- Mechanism-based PK–PD model for the prolactin biological system response following an acute dopamine inhibition challenge: quantitative extrapolation to humans (2012) (0)
- Modeling of the age-related pharmacokinetics in children. A date-driven analysis of Busulfan prior to haemopoietic stem cell transplantation (2011) (0)
- population pharmacokinetics of amikacin in neonates as a predictor for glomerular filtration rate (2009) (0)
- CD3+CD4+ and CD3+CD8+-Lymphocytes as Biomarkers Predicting the Long Term Outcome of Pediatric Haematopoietic Stem Cell Transplantation Recipients (2011) (0)
- Abstracts of papers clinical pharmacological meeting (2005) (0)
- Prediction of Disease Progression, Treatment Response and Dropout in Chronic Obstructive Pulmonary Disease (COPD) (2014) (0)
- Evaluation of current gentamicin and tobramycin dosing guidelines for neonates (2014) (0)
- Evaluation of the convulsive threshold as a marker for disease progression in the kainate post-SE model for temporal lobe epilepsy (2008) (0)
- Pharmacokinetic/Pharmacodynamic Modeling of Renin-Angiotensin Aldosterone Biomarkers Following Angiotensin-Converting Enzyme (ACE) Inhibition Therapy with Benazepril in Dogs (2014) (0)
- Mechanism-Based Pharmacodynamic Modeling of S( (cid:1) )-Atenolol: Estimation of in Vivo Affinity for the (cid:1) 1 -Adrenoceptor with an Agonist-Antagonist Interaction Model (2008) (0)
- Pharmacokinetic-pharmacodynamic modeling of the relationship between D2 receptor occupancy and catalepsy in rats (2012) (0)
- MEMBRANE TRANSPORT OF OPIOIDS: RELATIVE CONTRIBUTION OF P-GLYCOPROTEIN MEDIATED TRANSPORT AND PASSIVE PERMEABILITY IN VITRO (2007) (0)
- forGiveness of non-Adherence to once vs. tWice dAily lAmivudine/AbAcAvir in combinAtion With efAvirenz in hiv-infected children (2013) (0)
- Animal Models as a Tool in Systems Pharmacology Research on Parkinson's Disease (2009) (0)
- TRANSDERM AL IONTOPHORESIS OF 5-OH DPAT IN RATS : IN VITRO – IN VIVO CORRELATION (2005) (0)
- Exploratory analysis of the correlation between pain relief and target engagement in rheumatoid arthritis (2013) (0)
- Abstracts of papers and posters Meeting on Pharmaceutical Sciences (1993) (0)
- Functional Consequences of overexpression of Doublecortin Like Kinase gene products in the mouse hippocampus: Implications for development of epilepsy (2007) (0)
- (RCCT) in paediatric development: dealing with heterogeneity and uncertainty in pharmacokinetic trials in children (2011) (0)
- Prospective Validation of a Model-based Dosing Regimen for Amikacin in Preterm and Term Neonates (2014) (0)
- Modeling and simulation of placebo response and dropout patterns in treatment of schizophrenia (2010) (0)
- Physiologically Based Pharmacokinetic Modeling to Investigate Regional Brain Distribution Kinetics in Rats (2012) (0)
- Modeling and simulation of placebo response and dropout patterns in treatment of schizophrenia (2010) (0)
- A comparison oftheconcentration-ef fect relationships of midazolam forEEG-derived parameters andsaccadic peak velocity (1993) (0)
- 0050Translating the gap in the evaluation of drug-induced QTc-interval prolongation from in vivo to the clinic (2014) (0)
- predicting glomerular filtration rate using clearance of amikacin (2010) (0)
- Pharmacokinetic/Pharmacodynamic Correlations of Anticonvulsants (2019) (0)
- A Bodyweight-Dependent Allometric Exponent for Scaling Clearance Across the Human Life-Span (2012) (0)
- Chapter 6.qxd (2008) (0)
- Towards a mechanistic disease progression model for type 2 diabetes mellitus (2004) (0)
- 298 Cd3+Cd4+-Lymphocytes as Biomarker Predicting the Outcome of Pediatric Haematopoietic Stem Cell Transplantation Recipients (2010) (0)
- Pharmacokinetic-pharmacodynamic modelling of the core set of outcome measures (ACRn) in rheumatoid arthritis (2013) (0)
- TDM of everolimus in stable renal transplant patients after CNI withdrawal (2007) (0)
- The impact of P-glycoprotein functionality on non-steady state relationships between CSF and brain extracellular fluid (2014) (0)
- PP012—Not-in-trial simulations: Predicting cardiovascular risk from clinical trials to real life conditions (2013) (0)
- TRANSDERM AL IONTOPHORESIS OF ROTIGOTINE : INFLUENCE OF CONCENTRATION , TEM PERATURE AND CURRENT DENSITY IN HUM AN SKIN IN VITRO (2005) (0)
- Chapter 5.new.qxd (2008) (0)
- Simulations of vancomycin exposurein neonates upon commonly used dosing guidelines: towards a model-based dosing guideline (2014) (0)
- Optimisation of pharmacokinetic studies in children: a non-linear mixed effects approach (2011) (0)
- Abstracts of Dutch Ph.D. Theses (1981) (0)
- Scaling of propofol clearance form preterm neonates to adults (2009) (0)
- Translational modelling of prolactin response following administration of D2 antagonists in rats (2015) (0)
- Interactions study of the low molecular weight heparinoid Org 10172 (lomoparan®) and acetylsalicylic acid in healthy male volunteers (1990) (0)
- Inter-study variability and translational value of preclinical exposure-QTc predictions—A pharmacokinetic/pharmacodynamic (PK/PD) meta-analysis (2016) (0)
- Dopamine D2 Receptor Occupancy as a Predictor of Catalepsy in Rats: A Pharmacokinetic-Pharmacodynamic Modeling Approach (2014) (0)
- P165 PK/PD modelling of the anticonvulsant and EEG effects of phenytoin (1994) (0)
- Modulation of GABAergic inhibition by tiagabine and alphaxalone is differentially affected in the kainate model of temporal lobe epilepsy (2008) (0)
- Optimization of Anti-Thymocyte Globulin Exposure in Paediatric Bone Marrow Transplantation in Order to Design an individualized Dosing Regimen (2011) (0)
- Abstracts of papers (1966) (0)
- Response to letter to the editor from Dr. Mahmood (2015) (0)
- P.6.018 Assessment of the pharmacodynamic interaction between phenytoin and sodium valproate by ictal behaviour analysis (1996) (0)
- Model-based prediction of the effect of COX inhibitors and optimal dosing in patients with systemic lupus erythematosus (2008) (0)
- impAct of non-Adherence to AntiretrovirAl combinAtion therApy in hiv-infected children (2013) (0)
- Is age an important determinant of the kinetics of the anticonvulsant effect of oxazepam (1990) (0)
- To fail or not to fail - clinical trials in depression (2004) (0)
- Predictive performance of two PK-PD models of D2 receptor occupancy of the antipsychotics risperidone and paliperidone in rats (2010) (0)
- The relevance of absorption rate and lag time to the onset of action and pain relief in migraine (2007) (0)
- Abstracts of papers Pharmacological meeting (1985) (0)
- Translational pharmacology of dopamine receptor agonists and antagonists (2005) (0)
- Information-based adaptive designs for the assessment of efficacy of antidepressant drugs: A Bayesian framework for interim analysis accounting for enrolment rate (2008) (0)
- Translational Modeling in Schizophrenia: Predicting Human Dopamine D2 Receptor Occupancy (2015) (0)
- A195 PHARMACOKINETIC-PHARMACODYNAMIC MODELING OF THE INTERACTION BETWEEN FLUMAZENIL AND MIDAZOLAM WITH APERIODIC EEG ANALYSIS, IN VOLUNTEERS (1990) (0)
- Scaling clearance of propofol form preterm neonates to adults: a preliminary study on bodyweight based covariate models (2010) (0)
- Characterizing QT interval prolongation in early clinical development: a case study with methadone (2017) (0)
- Development of longitudinal PET studies for experimental animal models (2005) (0)
- PKPD correlations and biomarkers in the development of COX-2 inhibitors (2008) (0)
- CHARACTERISATION OF THE ROLE OF BIOPHASE DISTRIBUTION Sec 2 (2007) (0)
- O-107 Prospective Validation Of A Model-based Dosing Regimen For Amikacin In Preterm And Term Neonates (2014) (0)
- Evaluation of dosing regimen on amoxicillin exposure in pregnant women with preterm premature rupture of the membranes using Monte Carlo Simulation. (2009) (0)
- Kinetics of drug effects to optimise delivery to the brain (2001) (0)
- University of Groningen A new minimal-stress freely-moving rat model for preclinical studies on intranasal administration of CNS drugs Stevens, Jasper; Suidgeest, (2009) (0)
- First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development (2012) (0)
- Abstracts of papers Pharmacological Meeting (2005) (0)
- Knowledge Sharing, and Training Are Critical for Future Success Pharmacometrics as a Discipline Is Entering the ''Industrialization'' Phase: Standards, Automation, (2010) (0)
- Progesterone inSaliva:Pittalls andConsequent Implications forAccuracy of theDetermination (1986) (0)
- Alterations in GABAA receptor kinetics in epileptic rats studied in vivo using positron emission tomography (2006) (0)
- Translational pharmacology of intranasal administration of dopamine receptor agonists and antagonists (2011) (0)
- University of Groningen Pharmacokinetic-pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia (2013) (0)
- Model-based quantification of the relationship between age and anti-migraine therapy (2007) (0)
- Modeling and simulation for medical product development and evaluation: highlights from the FDA-C-Path-ISOP 2013 workshop (2014) (0)
- This material is the copyright of the original publisher. Unauthorised copying and distribution is prohibited. Body Weight-Dependent Pharmacokinetics of Busulfan in Paediatric Haematopoietic Stem Cell Transplantation Patients (2012) (0)
- Subject Index, Vol. 22, 1981 (1981) (0)
- Chapter 7 Pilot study on the influence of liver blood flow and cardiac output on the clearance of propofol in critically ill patients (2007) (0)
- Unravelling the relationship between exposure , biomarker and analgesic response to COX inhibitors in chronic inflammatory pain (2008) (0)
- Pharmacokinetic-pharmacodynamic modelling of the interaction between flumazenil and midazolam in volunteers using aperiodic EEG analysis (1990) (0)
- Erratum to: A Novel Maturation Function for Clearance of the Cytochrome P450 3A Substrate Midazolam from Preterm Neonates to Adults (2013) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Meindert Danhof?
Meindert Danhof is affiliated with the following schools:
